Cargando…

Do classical oestrogen markers predict for clinical response to endocrine therapy?

Detalles Bibliográficos
Autor principal:	Miller, William R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230527/ http://dx.doi.org/10.1186/bcr1817

Ejemplares similares

Markers of endocrine sensitivity
por: Hayes, Daniel F
Publicado: (2008)

The oestrogen paradox: an hypothesis
por: Santen, Richard J
Publicado: (2007)

Oestrogen receptors and the response to endocrine therapy in advanced breast cancer.
por: Roberts, M. M., et al.
Publicado: (1978)

Identification and mechanisms of endocrine resistance
por: Miller, William R
Publicado: (2008)

Oestrogen is bad for patients with breast cancer?
por: Jordan, V Craig, et al.
Publicado: (2007)

Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica
por: Condappa, Andrew, et al.
Publicado: (2018)

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
por: Smith, Ian E
Publicado: (2009)

The origins of oestrogen receptor negative breast cancer
por: Allred, D Craig
Publicado: (2007)

Assessing individual risk for breast cancer: role of oestrogens and androgens
por: Santen, Richard J
Publicado: (2008)

Current and future choices in endocrine therapy
por: Ellis, Matthew
Publicado: (2007)

Integration of endocrine therapy with targeted agents
por: Johnston, Stephen RD
Publicado: (2008)

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.
por: Leake, R. E., et al.
Publicado: (1981)

Oestrogenic Endocrine Disruptors in the Placenta and the Fetus
por: Tang, Zi-Run, et al.
Publicado: (2020)

The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer
por: Downey, C L, et al.
Publicado: (2014)

Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.
por: McClelland, R. A., et al.
Publicado: (1998)

Live or let die: oestrogen regulation of survival signalling in endocrine response
por: Butt, Alison J, et al.
Publicado: (2007)

The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy.
por: Hawkins, R. A., et al.
Publicado: (1988)

Breast cancer: a comparison of response to endocrine therapy and oestrogen excretion patterns including unusual metabolites.
por: Castagnetta, L., et al.
Publicado: (1981)

Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma.
por: Taylor, O. M., et al.
Publicado: (1992)

Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment
por: Miller, W R, et al.
Publicado: (2006)

Possible Association Between Melanoma Arising from Congenital Naevus and Oestrogen or Progesterone Receptor Expression: Clinicopathological Analysis
por: SUMITOMO, Chiho, et al.
Publicado: (2023)

Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors
por: Lee, Hye-Rim, et al.
Publicado: (2013)

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
por: Anderson, E. D., et al.
Publicado: (1989)

Endocrine and targeted treatments for breast cancer
por: Hudis, Clifford A
Publicado: (2007)

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
por: Ingle, James N
Publicado: (2008)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Classical peer review: an empty gun
por: Smith, Richard
Publicado: (2010)

Evaluation of chemoresponse assays as predictive markers
por: Korn, E L, et al.
Publicado: (2015)

Classic Kaposi's sarcoma in southern Sardinia, Italy
por: Atzori, L, et al.
Publicado: (2004)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer
por: Nurgalieva, A.K., et al.
Publicado: (2021)

Predictive markers of endocrine response in breast cancer
por: Mosly, Duniya, et al.
Publicado: (2018)

Bone turnover markers in epileptic patients under chronic valproate therapy
por: Zare, Mohammad, et al.
Publicado: (2013)

Dermoscopic Structures Predictive of Response to Photodynamic Therapy in Basal Cell Carcinoma
por: NAVARRO-BIELSA, Alba, et al.
Publicado: (2023)

DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
por: Stone, Andrew, et al.
Publicado: (2015)

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
por: Gellert, Pascal, et al.
Publicado: (2016)

Predicting response/resistance to endocrine therapy for breast cancer
por: Miller, WR, et al.
Publicado: (2005)

Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough?
por: Omrani, Ali S., et al.
Publicado: (2015)

Classic Hoarding Cages Increase Gut Bacterial Abundance and Reduce the Individual Immune Response of Honey Bee (Apis mellifera) Workers
por: Gregory, Casey L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2ktudn88e3pidnmt2a3lindvu